Screener
TG Therapeutics TGTX Payments For Repurchase Of Equity
Payments For Repurchase Of Equity at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfEquity.
The source filing: TG Therapeutics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-015246
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Proceeds from exercise of options | 763 | 21 |
| Proceeds from debt financings, net of debt discount costs | 747,656 | — |
| Financing costs paid | (2,598) | — |
| Purchase of treasury stock | (99,992) | (6,123) |
| Net cash provided by (used in) financing activities | 390,829 | (6,102) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 363,071 | (47,751) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 80,490 | 181,192 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | $443,561 | $133,441 |
Document
FAQ
- What is TG Therapeutics's payments for repurchase of equity?
- TG Therapeutics (TGTX) reported payments for repurchase of equity of $99.99M in Q1 2026.
- How has TG Therapeutics's payments for repurchase of equity changed year-over-year?
- TG Therapeutics's payments for repurchase of equity increased by 1533.1% year-over-year, from $6.12M to $99.99M.
- What does payments for repurchase of equity mean?
- Payments For Repurchase Of Equity
Ask your AI about TG Therapeutics's payments for repurchase of equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude